Publications by Thomas P Moyer, PhD
To read any of these publications, go to PubMed at < https://pubmed.ncbi.nlm.nih.gov/ >, enter “Moyer tp” and the first few words of the publication title.
Peer Reviewed Scientific Publications:
1. Moyer TP, Fischer AG. Purification and characterization of a purine-nucleoside phosphorylase from bovine thyroid. Arch Biochem Biophys. 1976 Jun; 174(2):622-9. PMID:7211.
2. Lee H, Carlson JD, McMahon KK, Moyer TP, Fischer AG. Xanthine oxidase: a source of hydrogen peroxide in bovine thyroid glands. Life Sci. 1977 Feb 1; 20(3):453-8. PMID:14288.
3. Moyer TP, Jiang NS. Optimized isocratic conditions for analysis of catecholamines by high-performance reversed-phase paired-ion chromatography with amperometric detection. J Chromatogr. 1978 Jul 3; 153:365-372.
4. Moyer TP, Carpenter PC, Jiang NS, Machacek D. Series on clinical testing. 2. Fractionation of urinary ketosteroids: procedure and clinical significance. Mayo Clin Proc. 1978 Sep; 53:601-606. PMID:150475.
5. Moyer TP, Jiang NS, Tyce GM, Sheps SG. Analysis for urinary catecholamines by liquid chromatography with amperometric detection: methodology and clinical interpretation of results. Clin Chem. 1979 Feb; 25(2):256-63. PMID: 759019.
6. Muldoon SM, Tyce GM, Moyer TP, Rorie DK. Measurement of endogenous norepinephrine overflow from saphenous veins. Am J Physiol. 1979 Feb; 236:H263-H267. PMID:420310.
7. Anhalt JP, Moyer TP. The role of gas-liquid chromatography and liquid chromatography in therapeutic drug monitoring. Laboratory Medicine. 1980; 11:797-806.
8. Moyer TP, Fischer AG, Schulz AR. Kinetic studies on bovine thyroidal purine nucleoside phosphorylase. Int J Biochem. 1980; 11(3-4):243-50. PMID:6771166.
9. Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL. Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy. Ann Intern Med. 1980 Mar; 92(3):384-5. PMID:7356232.
10. Tisdall PA, Moyer TP, Anhalt JP. Liquid-chromatographic detection of thiazide diuretics in urine. Clin Chem. 1980 May; 26(6):702-6. PMID:7371146.
11. Ames MM, Moyer TP, Kovach JS, Moertel CG, Rubin J. Pharmacology of amygdalin (laetrile) in cancer patients. Cancer Chemotherapy & Pharmacology. 1981; 6(1):51-7. PMID:7273266.
12. Moyer TP, Sheps SG. Antihypertensive agents: role of therapeutic drug monitoring. Ther Drug Monit. 1981; 3(3):217-30. PMID:7034303.
13. Moertel CG, Ames MM, Kovach JS, Moyer TP, Rubin JR, Tinker JH. A pharmacologic and toxicological study of amygdalin. JAMA. 1981 Feb 13; 245(6):591-4. PMID:7005480.
14. Yao JK, Dyck PJ, VanLoon JA, Moyer TP. Free fatty acid composition of human and rat peripheral nerve. J Neurochem. 1981 Mar; 36(3):1211-8. PMID:7205267.
15. Welch CL, Annesley TM, Luthra HS, Moyer TP. Liquid-chromatographic determination of zomepirac in serum and plasma. Clin Chem. 1982 Mar; 28(3):481-4. PMID:7067091.
16. Ducatman AM, Amundsen MA, Moyer TP. Case report: chronic nervous system disability-evaluation of the role of organophosphate pesticides. Am Assoc Clin Chem (Tdm - Therapeutic Drug Monitoring) 1982 Jul; 1-3.
17. Coulam CB, Moyer TP, Jiang NS, Zincke H. Breast-feeding after renal transplantation. Transplant Proc. 1982 Sep; 14(3):605-9. PMID:6817481.
18. Moyer TP, Maruta T, Richelson E, Richardson JW. The implications for antidepressant therapy of measurement of urinary MHPG. Mayo Clin Proc. 1982 Oct; 57(10):665-7. PMID:7121073.
19. McGoon MD, Seward JB, Vlietstra RE, Choo MH, Moyer TP, Reeder GS. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension. Br Heart J. 1983 Dec; 50(6):579-85. PMID:6652000. PMCID: 481463.
20. Sedman AJ, Gal J, Mastropaolo W, Johnson P, Maloney JD, Moyer TP. Serum tocainide enantiomer concentrations in human subjects. Br J Clin Pharmacol. 1984 Jan; 17(1):113-5. PMID:6419760. PMCID:1463303.
21. Mastropaolo W, Holmes DR, Osborn MJ, Rooke J, Moyer TP. Improved liquid-chromatographic determination of mexiletine, an antiarrhythmic drug, in plasma. Clin Chem. 1984 Feb; 30(2):319-22. PMID:6692546.
22. Nugent M, Tinker JH, Moyer TP. Verapamil worsens rate of development and hemodynamic effects of acute hyperkalemia in halothane-anesthetized dogs: effects of calcium therapy. Anesthesiology. 1984 May; 60(5):435-9. PMID:6424514.
23. Sill JC, Nugent M, Moyer TP, Torres LE, Schaff HV, Tinker JH. Influence of propranolol plasma levels on hemodynamics during coronary artery bypass surgery. Anesthesiology. 1984 May; 60(5):455-63. PMID:6608882.
24. Faynor SM, Moyer TP, Sterioff S, McDonald MW. Therapeutic drug monitoring of cyclosporine. Mayo Clin Proc. 1984 Aug; 59(8):571-2. PMID:6379321.
25. Sill JC, Nugent M, Moyer TP, Schaff H, Tinker JH. Plasma levels of beta-blocking drugs prior to coronary artery bypass surgery. Anesthesiology. 1985 Jan; 62(1):67-70. PMID:3871313.
26. Moyer TP, Charlson JR, Ebnet LE. Improved chromatography of cyclosporine. Ther Drug Monit. 1986; 8(4):466-8. PMID:3824434.
27. Nixon DE, Moyer TP, Windebank AJ, Webster DD, Mussmann GV, McCall JT. Lack of correlation of low levels of whole blood and serum lead in humans. An experimental evaluation of this relationship in animals. Trace Substances in Environmental Health XIX: 1986; 248-256.
28. Moyer TP, Johnson P, Faynor SM, Sterioff S. Cyclosporine: a review of drug monitoring problems and presentation of a simple, accurate liquid chromatographic procedure that solves these problems. Clin Biochem. 1986 Apr; 19(2):83-9. PMID:3518993.
29. Zachariah PK, Bloedow DC, Moyer TP, Sheps SG, Schirger A, Fealey RD. Pharmacodynamics of midodrine, an antihypotensive agent. Clinical Pharmacology & Therapeutics. 1986 May; 39(5):586-91. PMID:2421958.
30. Nixon DE, Moyer TP, Johnson P, McCall JT, Ness AB, Fjerstad WH, Wehde MB. Routine measurement of calcium, magnesium, copper, zinc, and iron in urine and serum by inductively coupled plasma emission spectroscopy. Clin Chem. 1986 Sep; 32(9):1660-5. PMID:3742794.
31. McCarthy JT, Milliner DS, Kurtz SB, Johnson WJ, Moyer TP. Interpretation of serum aluminum values in dialysis patients. Am J Clin Pathol. 1986 Nov; 86(5):629-36. PMID:3776914.
32. National Academy of Clinical Biochemistry/ American Association for Clinical Chemistry Task Forceon Cyclosporine Monitoring. Critical issues in cyclosporine monitoring: Report of the task force on cyclosporine monitoring. Clin Chem. 1987; 33:1269-88.
33. Post GR, Moyer TP, Anderson CF, Sterioff S. Long-term cyclosporine for renal allograft patients does not cause nephrotoxicity. Transplant Proc. 1987 Feb; 19(1 Pt 2):1761-3. PMID:3079036.
34. Moyer TP, Palmen MA, Johnson P, Charlson JR, Ellefson PJ. Marijuana testing--how good is it? Mayo Clin Proc. 1987 May; 62(5):413-7. PMID:3553756.
35. Fleischer JE, Milde JH, Moyer TP, Michenfelder JD. Cerebral effects of high-dose midazolam and subsequent reversal with Ro 15-1788 in dogs. Anesthesiology. 1988 Feb; 68(2):234-42. PMID:3124673.
36. Moyer TP, Post GR, Sterioff S, Anderson CF. Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. Mayo Clin Proc. 1988 Mar; 63(3):241-7. PMID:3278174.
37. de Groen PC, McCallum DK, Moyer TP, Wiesner RH. Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis. Transplant Proc. 1988 Apr; 20(2 Suppl 2):509-11. PMID:3363652.
38. Welsh PW, O'Connell EJ, Sachs MI, Moyer TP, Wick KA, Harrison LI, McCarville SE, Kvam DC. Pharmacokinetic properties of sustained-release theophylline (Theolair-SR) in relation to timing of doses after low-fat meals. Ann Allergy. 1989 May; 62(5):396-400. PMID:2719348.
39. McCarthy JT, Johnson WJ, Nixon DE, Jenson BM, Moyer TP. Transfusional iron overload in patients undergoing dialysis: treatment with erythropoietin and phlebotomy. J Lab Clin Med. 1989 Aug; 114(2):193-9. PMID:2754306.
40. Nixon DE, Moyer TP, Squillace DP, McCarthy JT. Determination of serum nickel by graphite furnace atomic absorption spectrometry with Zeeman-effect background correction: values in a normal population and a population undergoing dialysis. Analyst. 1989 Dec; 114(12):1671-4. PMID:2633657.
41. Moyer TP, et al. Consensus Document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Transplantation Proceedings. 1990; 22(3):1357-61. PMID:2190399.
42. Nelson PE, Moyer TP, Thistle JL. Gallstone dissolution in vitro using methyl tert-butyl ether: radiologic selection criteria. Gastroenterology. 1990 May; 98(5 Pt 1):1280-3. PMID:2323520.
43. Nelson PE, Moyer TP, Thistle JL. Dissolution of calcium bilirubinate and calcium carbonate debris remaining after methyl tert-butyl ether dissolution of cholesterol gallstones. Gastroenterology. 1990 May; 98(5 Pt 1):1345-50. PMID:2323524.
44. Martin RW, Duffy J, Engel AG, Lie JT, Bowles CA, Moyer TP, Gleich GJ. The clinical spectrum of the eosinophiliamyalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med. 1990 Jul 15; 113(2):124-34. PMID:2360751.
45. Kachel DL, Moyer TP, Martin WJ 2nd. Amiodarone-induced injury of human pulmonary artery endothelial cells: protection by alpha-tocopherol. Journal of Pharmacology & Experimental Therapeutics. 1990 Sep; 254(3):1107-12. PMID:2395108.
46. Zachariah PK, Moyer TP, Theobald HM, Frantz RP, Kurtz SB, McCarthy JT, Smith RL. The pharmacokinetics of racemic verapamil in patients with impaired renal function. J Clin Pharmacol. 1991 Jan; 31(1):45-53. PMID:2045528.
47. McCarthy JT, Hodgson SF, Fairbanks VF, Moyer TP. Clinical and histologic features of iron-related bone disease in dialysis patients. Am J Kidney Dis. 1991 May; 17(5):551-61. PMID:2024657.
48. Moyer TP, Mussmann GV, Nixon DE. Blood-collection device for trace and ultra-trace metal specimens evaluated. Clin Chem. 1991 May; 37(5):709-14. PMID:2032325.
49. Hayes SN, Moyer TP, Morley D, Bove AA. Intravenous cocaine causes epicardial coronary vasoconstriction in the intact dog. Am Heart J. 1991 Jun; 121(6 Pt 1):1639-48. PMID:2035378.
50. Moyer TP, Winkels J, Krom R, Wiesner R. Evaluation of Abbott TDx monoclonal assay of cyclosporine in whole blood. Clin Chem. 1991 Jun; 37(6):1120-1. PMID:2049832.
51. Nixon DE, Mussmann GV, Eckdahl SJ, Moyer TP. Total arsenic in urine: palladium-persulfate vs nickel as a matrix modifier for graphite furnace atomic absorption spectrophotometry. Clin Chem. 1991 Sep; 37(9):1575-9. PMID:1893592.
52. Nixon DE, Moyer TP. Arsenic analysis II: rapid separation and quantification of inorganic arsenic plus metabolites and arsenobetaine from urine. Clin Chem. 1992 Dec; 38(12):2479-83. PMID:1458588.
53. Herkes GK, Eadie MJ, Sharbrough FW, Moyer TP. Patterns of seizure occurrence in catamenial epilepsy. Epilepsy Research. 1993; 15:47-52. PMID:8325277.
54. Ludwig J, Batts KP, Moyer TP, Baldus WP, Fairbanks VF. Liver biopsy diagnosis of homozygous hemochromatosis: a diagnostic algorithm. Mayo Clin Proc. 1993 Mar; 68(3):263-7. PMID:8474269.
55. Lieberman N, Plevak D, Moyer T, Rettke S, Raasch R, Southorn P. Is it important to measure magnesium concentrations during and immediately after liver transplantation? Transplant Proc. 1993 Apr; 25(2):1826-7. PMID:8470183.
56. Morgenstern BZ, Milliner DS, Murphy ME, Simmons PS, Moyer TP, Wilson DM, Smith LH. Urinary oxalate and glycolate excretion patterns in the first year of life: a longitudinal study. J Pediatr. 1993 Aug; 123(2):248-51. PMID:8345420.
57. Moyer TP. Testing for arsenic. Mayo Clin Proc. 1993 Dec; 68(12):1210-1. PMID:8246626.
58. Ludwig J, Batts KP, Moyer TP, Poterucha JJ. Advances in liver biopsy diagnosis. Mayo Clin Proc. 1994 Jul; 69(7):677-8. PMID:8015333.
59. Ludwig J, Moyer TP, Rakela J. The liver biopsy diagnosis of Wilson's disease. Methods in pathology. Am J Clin Pathol. 1994 Oct; 102(4):443-6. PMID:7942601.
60. Bush VJ, Moyer TP, Batts KP, Parisi JE. Essential and toxic element concentrations in fresh and formalin-fixed autopsy tissues. Clin Chem. 1995 Feb; 41:284-294. PMID:7874782.
61. Alzaid AA, Dinneen SF, Moyer TP, Rizza RA. Effects of insulin on plasma magnesium in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab. 1995 Apr; 80(4):1376-81. PMID:7714113.
62. Ahlskog JE, Waring SC, Kurland LT, Petersen RC, Moyer TP, Harmsen WS, Maraganore DM, O'Brien PC, EstebanSantillan C, Bush V. Guamanian neurodegenerative disease - investigation of the calcium metabolism heavy metal hypothesis. Neurology. 1995 Jul; 45:1340-4. PMID:7617195.
63. Ho J, Moyer TP, Phillips SF. Chronic diarrhea: the role of magnesium. Mayo Clin Proc. 1995 Nov; 70(11):1091-2. PMID: 7475340.
64. Fleming CR, George L, Stoner GL, Tarrosa VB, Moyer TP. The importance of urinary magnesium values in patients with gut failure. Mayo Clin Proc. 1996 Jan; 71(1):21-4. PMID:8538226.
65. Nixon DE, Mussmann GV, Moyer TP. Inorganic, organic, and total mercury in blood and urine: cold vapor analysis with automated flow injection sample delivery. J Anal Toxicol. 1996 Jan-Feb; 20(1):17-22. PMID:8837946.
66. Nixon DE, Moyer TP. Routine clinical determination of lead, arsenic, cadmium, and thallium in urine and whole blood by inductively coupled plasma mass spectrometry. Spectrochim Acta B. 1996 Jan 15; 51(1):13-25.
67. Schnur PL, Weinzweig J, Harris JB, Moyer TP, Petty PM, Nixon D, McConnell JP. Silicon analysis of breast and periprosthetic capsular tissue from patients with saline or silicone gel breast implants. Plast Reconstr Surg. 1996 Oct; 98(5):798-803. PMID:8823017.
68. McConnell JP, Moyer TP, Nixon DE, Schnur PL, Salomao DR, Crotty TB, Weinzweig J, Harris JB, Petty PM. Determination of silicon in breast and capsular tissue from patients with breast implants performed by inductively coupled plasma emission spectroscopy. Comparison with tissue histology. Am J Clin Pathol. 1997 Feb; 107(2):236-46. PMID: 9024074.
69. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology. 1997 Mar; 112(3):882-8. PMID:9041250.
70. Moyer TP, Oliver LK. Supporting pharmaceutical studies for FDA submissions: diversifying the drug monitoring laboratory. Clin Chem. 1998 Feb; 44(2):433-6. PMID:9474056.
71. Weinzweig J, Schnur PL, McConnell JP, Harris JB, Petty PM, Moyer TP, Nixon D. Silicon analysis of breast and capsular tissue from patients with saline or silicone gel breast implants: II. Correlation with connective-tissue disease. Plastic & Reconstructive Surgery. 1998 Jun; 101(7):1836-41. PMID:9623824.
72. Hurt RD, Offord KP, Croghan IT, Croghan GA, Gomez-Dahl LC, Wolter TD, Dale LC, Moyer TP. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology (Berl) 1998 Nov; 140(1):98-104. PMID:9862408.
73. Pettersen MD, Driscoll DJ, Moyer TP, Dearani JA, McGregor CG. Measurement of blood serum cyclosporine levels using capillary "fingerstick" sampling: a validation study. Transpl Int. 1999; 12(6):429-32. PMID:10654354.
74. Nixon DE, Moyer TP, Burritt MF. The determination of selenium in serum and urine by inductively coupled plasma mass spectrometry: comparison with Zeeman graphite furnace atomic absorption spectrometry. Spectrochim Acta B. 1999 Jun 14; 54(6):931-42.
75. Nixon DE, Burritt MF, Moyer TP. The determination of mercury in whole blood and urine by inductively coupled plasma mass spectrometry. Spectrochim Acta B. 1999 Aug 9; 54(8):1141-53.
76. Moyer TP, Temesgen Z, Enger R, Estes L, Charlson J, Oliver L, Wright A. Drug monitoring of antiretroviral therapy for HIV-I infection: method validation and results of a pilot study. Clin Chem. 1999 Sep; 45(9):1465-1476. PMID:10471649.
77. Ogburn PL Jr, Hurt RD, Croghan IT, Schroeder DR, Ramin KD, Offord KP, Moyer TP. Nicotine patch use in pregnant smokers: nicotine and cotinine levels and fetal effects. Am J Obstet Gynecol. 1999 Sep; 181(3):736-43. PMID: 10486492.
78. Hurt RD, Ahlskog JE, Croghan GA, Offord KP, Wolter TD, Croghan IT, Moyer TP. Carbidopa/levodopa for smoking cessation: a pilot study with negative results. Nicotine & Tobacco Research. 2000; 2:71-8. PMID:11072443.
79. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, Golden D, Neumayr L, Vichinsky E. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood. 2000 Jul 1; 96(1): 76-9. PMID:10891433.
80. Clouse WD, Yamaguchi H, Phillips MR, Hurt RD, Fitzpatrick LA, Moyer TP, Rowland C, Schaff HV, Miller VM. Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts. J Appl Physiol. 2000 Sep; 89(3):1213-23. PMID:10956371.
81. Ogburn P, Ramin K, Schroeder D, Hurt R, Croghan I, Offord K, Moyer T. Long term nicotine patch use in pregnancy: safety and effectiveness. Am J Obstet Gynecol. 2001; 185(6):S120.
82. Roberts WL, Annesley TM, De BK, Moulton L, Juenke JM, Moyer TP. Performance characteristics of four free phenytoin immunoassays. Ther Drug Monit. 2001 Apr; 23(2):148-54. PMID:11294515.
83. Schroeder DR, Ogburn PL Jr, Hurt RD, Croghan IT, Ramin KD, Offord KP, Moyer TP. Nicotine patch use in pregnant smokers: smoking abstinence and delivery outcomes. J Matern Fetal Neonatal Med. 2002 Feb; 11(2):100-7. PMID: 12375538.
84. Moyer TP, Charlson JR, Enger RJ, Dale LC, Ebbert JO, Schroeder DR, Hurt RD. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clin Chem. 2002 Sep; 48(9):1460-71. PMID:12194923.
85. Wu AHB, McKay C, Broussard LA, Hoffman RS, Kwong TC, Moyer TP, Otten EM, Welch SL, Wax P. National academy of clinical biochemistry laboratory medicine practice guidelines: Recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin Chem. 2003 Mar; 49(3):357-79. PMID: 12600948.
86. Ebbert JO, Dale LC, Nirelli LM, Schroeder DR, Moyer TP, Hurt R. Cotinine as a biomarker of systemic nicotine exposure in spit tobacco users. Addict Behav. 2004 Feb; 29(2):349-55. PMID:14732423.
87. Butensky E, Fischer R, Hudes M, Schumacher L, Williams R, Moyer TP, Vichinsky E, Harmatz P. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol. 2005 Jan; 123(1):146-52. PMID:15762291.
88. Hurt RD, Renner CC, Patten CA, Ebbert JO, Offord KP, Schroeder DR, Enoch CC, Gill L, Angstman SE, Moyer TP. Iqmik - A form of smokeless tobacco used by pregnant Alaska natives: Nicotine exposure in their neonates. Journal of Maternal-Fetal & Neonatal Medicine. 2005 Apr; 17(4):281-9. PMID:16147838.
89. Renner CC, Enoch C, Patten CA, Ebbert JO, Hurt RD, Moyer TP, Provost EM. Iqmik: A form of smokeless tobacco used among Alaska Natives. Am J Health Behav. 2005 Nov-Dec; 29(6):588-94. PMID:16336113.
90. Woodworth A, Saunders AN, Koenig JW, Moyer TP, Turk J, Dietzen DJ. Differentiation of amphetamine/ methamphetamine and other cross-immunoreactive sympathomimetic amines in urine samples by serial dilution testing. Clin Chem. 2006 Apr; 52(4):743-6. Epub 2006 Feb 02. PMID:16455869. DOI:10.1373/clinchem.2005.060616.
91. Ebbert JO, Dale LC, Patten CA, Croghan IT, Schroeder DR, Moyer TP, Hurt RD. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. Nicotine Tob Res. 2007 Jan; 9(1):43-52. PMID:17365735.
92. Wilkins BW, Hesse C, Sviggum HP, Nicholson WT, Moyer TP, Joyner MJ, Eisenach JH. Alternative to ganglionic blockade with anticholinergic and alpha-2 receptor agents. Clin Auton Res. 2007 Apr; 17(2):77-84. Epub 2006 Dec 11. PMID:17160588. DOI:10.1007/s10286-006-0387-7.
93. Ebbert JO, Post JA, Moyer TP, Dale LC, Schroeder DR, Hurt RD. Nicotine percentage replacement among smokeless tobacco users with nicotine patch. Drug Alcohol Depend. 2007 Jul 10; 89(2-3):223-6. Epub 2007 Feb 14. PMID: 17300878. PMCID:2679895. NIHMS:24256. DOI:10.1016/j.drugalcdep.2006.12.034.
94. Wilkins BW, Hesse C, Charkoudian N, Nicholson WT, Sviggum HP, Moyer TP, Joyner MJ, Eisenach JH. Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May; 83(5):692-701. Epub 2007 Aug 08. PMID:17687267. DOI:10.1038/sj.clpt.6100326.
95. Leung N, Pittelkow MR, Lee CU, Good JA, Hanley MM, Moyer TP. Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis. Nephrology Dialysis Transplantation (NDT Plus) 2009; 2:309-11.
96. Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, Dupras DM, Chaudhry R, Thapa P, Zinsmeister AR, Heit JA. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009 Dec; 84(12):1079 PMID:19955245. PMCID:2787394. DOI:10.4065/mcp.2009.0278.
97. Epstein RS, Moyer TP, Aubert RE, O Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol. 2010 Jun 22; 55(25):2804-12. Epub 2010 Apr 08. PMID:20381283. DOI:10.1016/j.jacc.2010.03.009.
98. Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2011 Jan; 64(1):91-6. Epub 2010 Oct 30. PMID:21036418. DOI:10.1016/j.jaad.2009.12.044.
99. McAlpine DE, Biernacka JM, Mrazek DA, O'Kane DJ, Stevens SR, Langman LJ, Courson VL, Bhagia J, Moyer TP. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit. 2011 Feb; 33(1): 14-20. PMID:21099743. DOI:10.1097/FTD.0b013e3181fcf94d.
100.Wermers RA, Cooper K, Razonable RR, Deziel PJ, Whitford GM, Kremers WK, Moyer TP. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. 2011 Mar 1; 52(5):604-11. Epub 2011 Jan 16. PMID:21239842. DOI:10.1093/cid/ciq188.
101.Moyer TP, Highsmith WE, Smyrk TC, Gross JB Jr. Hereditary hemochromatosis: laboratory evaluation. Clin Chim Acta. 2011 Aug 17; 412(17-18):1485-92. Epub 2011 Apr 13. PMID:21510925. DOI:10.1016/j.cca.2011.04.007.
102.Coats D, Shelton-Dodge K, Ou K, Khun V, Seab S, Sok K, Prou C, Tortorelli S, Moyer TP, Cooper LE, Begley TP, Enders F, Fischer PR, Topazian M. Thiamine deficiency in Cambodian infants with and without beriberi. J Pediatr. 2012 Nov; 161(5):843-7. Epub 2012 Jun 14.
103.Schmitt BH, Feder MT, Rokke DL, Moyer TP, Pritt BS. An unusual foreign body in the urinary bladder mimicking a parasitic worm. J Clin Microbiol. 2012 Jul; 50 (7):2520-2 Epub 2012 Apr 25.
104.Estey MP, Diamandis EP, Van Der Straeten C, Tower SS, Hart AJ, Moyer TP. Cobalt and chromium measurement in patients with metal hip prostheses. Clin Chem. 2013 Jun; 59(6):880-6. Epub 2012 Oct 31.
105.Lieske JC, Rule AD, Krambeck AE, Williams JC, Bergstralh EJ, Mehta RA, Moyer TP. Stone composition as a function of age and sex. Clin J Am Soc Nephrol. 2014 Dec 5; 9 (12):2141-6 Epub 2014 Oct 02.
106.Morbeck DE, Krisher RL, Herrick JR, Baumann NA, Matern D, Moyer T. Composition of commercial media used for human embryo culture. Fertil Steril. 2014 Sep; 102(3):759-766.e9. Epub 2014 Jul 04.
107. Morbeck DE, Paczkowski M, Fredrickson JR, Krisher RL, Hoff HS, Baumann NA, Moyer T, Matern D. Composition of protein supplements used for human embryo culture. J Assist Reprod Genet. 2014 Dec; 31 (12):1703-11 Epub 2014 Sept 27.
108. Tolan NV, Sierra RJ, Moyer TP. Evidence against implant-derived cobalt toxicity: case report and retrospective study of serum cobalt concentrations in an orthopedic implant population. Clin Biochem. 2015 Feb; 48: (3)130-4.
Books Published
1. Moyer TP, Boeckx RL. Applied Therapeutic Drug Monitoring. Vol. 1. Fundamentals. TP Moyer and RL Boeckx, Editors. Washington, DC: American Association for Clinical Chemistry; 1982. (Book)
2. Moyer TP, Boeckx RL. Applied Therapeutic Drug Monitoring. Volume II: Review and Case Studies. Washington, DC: AACC Press; 1984. (Book)
Medical Textbook Chapters
1. Muldoon SM, Tyce GM, Moyer TP, Rorie DK. High pressure liquid chromatographic analysis of endogenous norepinephrine (NE) released from canine saphenous veins. In: Usdin E, Kopin I, Barchas J, editors. Catecholamines: Basic and Clinical Frontiers. Vol. 2. (Proceedings. 4th Internatl. Catecholamine Symposium. Pacific Grove, CA., Sept. 17-22, 1978.). Pergamon Press; 1978. p. 1488-90.
2. Moyer TP, Jiang NS, Machacek D. Analysis of urinary and plasma catecholamines by high-performance liquid chromatography with amperometric detection. In: Hawk GL, editor. Biological/Biomedical Applications of Liquid Chromatography II. New York: Marcel Dekker, Inc.; 1979. p. 75-92.
3. Moyer TP. Review of the uncommonly used antiepileptic drugs and the methods employed for their analysis. In: Moyer TP, Boeckx RL, editors. Applied Therapeutic Drug Monitoring. Volume 1. Washington, DC: The American Association for Clinical Chemistry; 1982. p. 161-6.
4. Moyer TP. Practical therapeutic drug monitoring. 279-322 in: Clinical Laboratory Annual. H.A. Homburger, J.G. Batsakis, Editors. Volume 2. East Norwalk, CT: Appleton-Century-Crofts, 1983.
5. Moyer TP. Antihypertensive agents: the role of therapeutic drug monitoring. In: Moyer TP, Boeckx RL, editors. Applied Therapeutic Drug Monitoring. Volume II: Review and Case Studies. Volume II. Washington, DC: AACC Press; 1984. p. 291-8.
6. Moyer TP. Drug induced cyanide intoxication: two cases. In: Moyer TP, Boeckx RL, editors. Applied Therapeutic Drug Monitoring. Volume II: Review and Case Studies. Volume II. Washington, DC: AACC Press; 1984. p. 305-8.
7. Wick MR, Moyer TP. Therapeutic monitoring of procainamide levels: clinical correlation. In: Moyer TP, Boeckx RL, editors. Applied Therapeutic Drug Monitoring. Volume II: Review and Case Studies. Volume II. Washington, DC: AACC Press; 1984. p. 129-33.
8. Moyer TP, Anhalt JP. Analysis of diuretics in urine. In: Sunshine I, editor. Methodology for Analytical Chemistry. Volume 3, Boca Raton: CRC Press; 1985. p. 79-83.
9. Moyer TP, Pippenger CE, Blanke RV, Blouin RA. Therapeutic drug monitoring. In: Tietz NW, editor. Textbook of Clinical Chemistry. Philadelphia: W. B. Saunders Co.; 1986. p. p. 1615-69.
10. Gorski JP, Bronk JT, Moyer TP. Mineralization of healing canine tibial defects. In: Development and Diseases of Cartilage and Bone Matrix. New York: Alan R. Liss, Inc.; 1987. p. 377-87.
11. Moyer TP, Pippenger CE Jr, Blanke RV, Blouin RA. Therapeutic drug monitoring. In: Tietz NW, editor. Fundamentals of Clinical Chemistry. 3rd Edition. Philadelphia: W. B. Saunders Co.; 1987. p. 842-68.
12. Moyer TP, Lawson GM. Therapeutic drug monitoring. In: McClatchey KD, editor. Clinical Laboratory Medicine. Baltimore: Williams and Wilkins; 1994. p. 417-44.
13. Moyer TP, Pippenger CE. Therapeutic drug monitoring. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. Second Edition. Philadelphia: W. B. Saunders Company; 1994. p. 1094-154.
14. Porter WH, Moyer TP. Clinical toxicology. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. Second Edition. Philadelphia: W. B. Saunders Company; 1994. p. 1155-235.
15. Moyer TP, Pippenger CE. Therapeutic drug monitoring. In: Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical Chemistry. Fourth Edition. Philadelphia: W. B. Saunders Company; 1996. p. 402-26.
16. Porter WH, Moyer TP. Clinical toxicology. In: Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical Chemistry. Fourth Edition. Philadelphia: W. B. Saunders Company; 1996. p. 427-56.
17. Moyer TP. Environmental poisons - toxic metals. IN: Self Study Guide in Toxicology. Poklis A, Nichols JH, editors. Amer. Assoc. Clin. Chem., 1998.
18. Moyer TP. Therapeutic drug monitoring. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. Third Edition. Philadelphia: W. B. Saunders Company; 1999. p. 862-905.
19. Moyer TP. Toxic metals. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. Third Edition. Philadelphia: W. B. Saunders Company; 1999. p. 982-98.
20. Moyer TP. Therapeutic drug monitoring. In: Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical Chemistry. 5th Edition. Philadelphia: W. B. Saunders; 2001. p. 608-35.
21. Porter WH, Moyer TP. Clinical toxicology. In: Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical Chemistry. 5th Edition. Philadelphia: W. B. Saunders; 2001. p. 636-79.
22. Wilke RA, Moyer TP. Neurotoxic metals. In: Noseworthy JH, editor. Neurological therapeutics : principles and practice. Volume 2. London: Martin Dunitz; 2003. p. 2223-8.
23. Moyer TP, Shaw LM. Therapeutic Drug Monitoring. In: Tietz Textbook of Clinical Chemistry. Burtis CA, Ashwood ER, Bruns DA. Fourth Edition. Philadelphia: W. B. Saunders Company; 2005. p. 1237-85.
24. Moyer TP. Toxic metals. In: Tietz Textbook of Clinical Chemistry. Burtis CA, Ashwood ER, Bruns DA. Fourth Edition. Philadelphia: W. B. Saunders Company; 2005. p. 1371-90.
25. Kumar N, Moyer TP. Neurotoxic metals. In: Noseworthy JH, editor. Neurological therapeutics: principles and practice. 2nd Edition. Volume 2. Abingdon: Informa Healthcare; 2006. p. 1716-35.
26. Moyer TP, Burritt MF, Butz J. Toxic metals. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 4th Edition. St. Louis: Elsevier Saunders; 2006. p. 1371-90.
27. Moyer TP, Shaw LM. Therapeutic drugs and their management. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 4th Edition. St. Louis: Elsevier Saunders; 2006. p. 1237-85.
28. Moyer TP, Burritt MF, Butz JA. Toxic metals. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz fundamentals of clinical chemistry. 6th Edition. St. Louis: Saunders Elsevier; 2008. p. 603-13.
29. Moyer TP, McMillin GA. Therapeutic drugs. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz fundamentals of clinical chemistry. 6th Edition. St. Louis: Saunders Elsevier; 2008. p. 539-61.
30. Moyer TP. Medical toxicology and antidotes. In: Waldman SA, Terzic A, editors. Pharmacology and therapeutics: principles to practice. Philadelphia: Saunders/Elsevier; 2009. p. 1213-20.
31. Moyer TP. The role of TDM in antihypertensives. Clin Chem. 1982 Apr; 26-7, 30, 42.
32. Moyer TP, Nixon DE, Ash KO. Filter paper lead testing. Clin Chem. 1999 Dec; 45(12):2055-6. PMID:10585335.
33. O'Kane DJ, Weinshilboum RM, Moyer TP. Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics. 2003; 4(1):1-4. PMID:12517278.